SMIM10L2A: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: SMIM10L2A

NCBI ID: G399668

SMIM10L2A

SMIM10L2A: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Introduction

Small intergenic non-protein coding RNAs (siNPCRs) are a class of non-coding RNAs that are involved in the regulation of gene expression. These RNAs are not translated into proteins but rather act as molecular regulators, involved in the control of gene expression, cell growth, and development. SMIM10L2A is a typical example of a siNPCR, and its function and potential as a drug target or biomarker are under investigation.

SMIM10L2A Expression and Localization

SMIM10L2A is a 21-kDa RNA molecule that is expressed in various tissues and cell types. It has been shown to be highly expressed in the brain, heart, and tests, and is also present in the liver, spleen, and peripheral blood cells. SMIM10L2A is primarily expressed in the cytoplasm and is located in the nuclear pore complex, a sub-nuclear membrane structure, whereas its translation product SMIM10L2A is a protein that contains 101 amino acids and has been shown to have various functions in cell signaling pathways, such as cell adhesion, migration, and invasion.

SMIM10L2A Interaction with Proteins

SMIM10L2A has been shown to interact with various proteins, including the transcription factor, NF-kappa-B, and the protein kinase, p300. These interactions may play a role in the regulation of gene expression and the control of cellular processes. For example, studies have shown that SMIM10L2A can interact with the transcription factor, NF-kappa-B, and that this interaction may be involved in the regulation of cell adhesion and migration.

SMIM10L2A as a Drug Target

SMIM10L2A has been shown to be a potential drug target in various cell types, including cancer cells. Studies have shown that inhibiting the activity of SMIM10L2A can lead to the inhibition of cell growth and the inhibition of the angiogenesis that may contribute to the development of cancer . Additionally, overexpression of SMIM10L2A has been shown to promote the growth of cancer cells, suggesting that it may also be a useful biomarker for the evaluation of cancer therapeutic approaches.

SMIM10L2A as a Biomarker

SMIM10L2A has also been shown to be a potential biomarker for various diseases, including cancer. The expression of SMIM10L2A has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that the expression of SMIM10L2A is associated with the poor prognosis of cancer patients. These findings suggest that SMIM10L2A may be a useful biomarker for the evaluation of cancer risk and the development of cancer therapies.

Conclusion

SMIM10L2A is a long intergenic non-protein coding RNA that has been shown to have various functions in cell signaling pathways. Its expression and localization have been shown to be involved in the regulation of gene expression, cell growth, and development. SMIM10L2A has also been shown to interact with various proteins and may be a potential drug target or biomarker for the evaluation of various diseases. Further research is needed to fully understand the role of SMIM10L2A in cellular processes and its potential as a drug target or biomarker.

Protein Name: Small Integral Membrane Protein 10 Like 2A

The "SMIM10L2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM10L2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets